CORTIMENT (budesonide), corticosteroid for local use
GASTROENTEROLOGY - New medicinal product
Opinions on drugs - Posted on Mar 29 2017
Reason for request
- CORTIMENT has Marketing Authorisation for inducing remission in mild to moderate forms of ulcerative colitis (UC) for which treatment with 5-ASA is not sufficient.
- Its efficacy is modest, but it has fewer side effects than systemic corticosteroid therapy.
- It has not been compared with an active treatment: 5-ASA or especially a systemic corticosteroid.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments